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Background: There are no definitive markers to aid in diagnosis of neonatal enceph-
alopathy (NE). The purpose of our study was (1) to identify and evaluate the utility of 
neuronal nitric oxide synthase (NOS1) in umbilical cord blood as a NE biomarker and (2) 
to identify the source of NOS1 in umbilical cord blood.
Methods: This was a nested case–control study of neonates >35 weeks of gestation. 
ELISA for NOS1 in umbilical cord blood was performed. Sources of NOS1 in umbilical 
cord were investigated by immunohistochemistry, western blot, ELISA, and quantitative 
PCR. Furthermore, umbilical cords of full-term neonates were subjected to 1% hypoxia 
ex vivo.
results: NOS1 was present in umbilical cord blood and increased in NE cases com-
pared with controls. NOS1 was expressed in endothelial cells of the umbilical cord vein, 
but not in artery or blood cells. In ex vivo experiments, hypoxia was associated with 
increased levels of NOS1 in venous endothelial cells of the umbilical cord as well as in 
ex vivo culture medium.
conclusion: This is the first study to investigate an early marker of NE. NOS1 is elevated 
with hypoxia, and further studies are needed to investigate it as a valuable tool for early 
diagnosis of neonatal brain injury.
Keywords: neonatal encephalopathy, biomarkers, umbilical veins, nOs1, diagnosis
inTrODUcTiOn
Neonatal encephalopathy (NE) affects 1–9 out of every 1,000 newborns (1, 2) and has a fatality 
rate of 9–70% (1, 3, 4); yet, it is still poorly diagnosed at birth. Clinically, NE may manifest as a 
subnormal level of consciousness or seizures, and is often accompanied by difficulty with initiating 
and maintaining respiration and depression of tone and reflexes (5). The extent of the brain injury 
TaBle 2 | stringent criteria for neonatal encephalopathy and 
neurologically normal neonates.
encephalopathic neonates neurologically normal neonates
At least one clinical criteria
•	 Lethargy
•	 Stupor or coma
•	 Decreased or no activity
•	 Distal flexion or complete extension
•	 Decerebrate posture
•	 Hypotonia or flaccidity
•	 Abnormal primitive reflexes
•	 Abnormal autonomic nervous system
•	 Seizures
Neurologically normal exam
Umbilical cord pH < 7.0 Umbilical cord pH > 7.2
Base deficit >12 Base deficit < 8
TaBle 1 | Maternal demographics and perinatal outcomes for neonatal 
encephalopathy (ne) cases and normal controls.
characteristic neurologically 
normal controls 
(n = 37)
ne cases 
(n = 27)
P value
Gestational age at delivery 
(weeks)
39.6 ± 1.0 39.2 ± 1.4 0.70
Maternal age (years) 26.5 ± 5.7 27 ± 7.6 0.63
Nulliparous 17 (61%) 15 (56%) 0.70
White race 7 (28%) 10 (37%) 0.33
Preeclampsiaa 3 (11%) 2 (7%) 0.18
Clinical chorioamnionitisa 4 (14%) 3 (11%) 0.72
Intrauterine growth restrictiona 3 (11%) 2 (7%) 0.97
Cesarean delivery 15 (54%) 20 (74%) 0.11
Infant male sex 18 (64%) 17 (63%) 0.92
Data are presented as means and SD for the two continuous variables, and counts and 
percentages for the seven categorical variables.
aRisk factors associated with NE.
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is later assessed by cranial ultrasound and MRI (6). Children 
diagnosed by clinical and neuroimaging criteria are at an increased 
risk of developing adverse long-term neurologic sequelae such as 
seizures and cognitive and motor difficulties (7).
Therapeutic hypothermia is the major medical treatment 
with promising long-term neurodevelopmental results, and this 
treatment is effective only when it is administered in the first six 
postnatal hours (8). Even with this treatment, approximately 40% 
of patients are affected with sequelae (8). A significant challenge 
in a timely treatment of NE is that the diagnosis and classification 
of the severity of the condition are often made only after the brain 
injury has already occurred. Based on easily accessible material, 
such as umbilical cord blood, early and prompt diagnosis of NE 
and associated prognosis would allow early intervention with 
hypothermia (9), erythropoietin (10), collection of umbilical 
cord blood for autologous stem cell transplantation (11), or 
stratification to other emerging therapies. Furthermore, provi-
sion of information to the injured neonates’ families, who may 
face difficult therapeutic decisions, is a key for early intervention.
Given that NE is a rare diagnosis, studies implementing 
ancillary markers for the diagnosis of the condition are limited. 
Several biomarkers such as glial fibrillary acidic protein (GFAP), 
S100 calcium-binding protein B (S100B), neuron-specific enolase 
(NSE), adrenomedullin, and activin A were investigated, but none 
of them presented an opportunity for early diagnosis (12–15). 
A plausible candidate early marker of neurologic injury in neo-
nates is neuronal nitric oxide synthase (NOS1). The association 
of the enzyme with adverse neurodevelopment is supported by 
animal studies (16, 17). In addition to neurons, NOS1 expres-
sion has been observed in non-neuronal tissues such as skeletal 
muscle, smooth muscle, and endothelial cells to control muscle 
contractility and local blood flow (18–20). Furthermore, studies 
have shown that NOS1 is expressed in cardiomyocytes in response 
to oxidative stress (21).
We hypothesized that NOS1 in umbilical cord blood is a 
plausible clinical biomarker for identification of NE due to 
hypoxic–ischemic events. To test our hypothesis, we pursued four 
aims: (1) to determine whether NOS1 is present not only in the 
umbilical cord but also in the umbilical cord blood of neonates; 
(2) to determine whether the level of NOS1 in neonates with a 
clinical diagnosis of NE is significantly different from that of neu-
rologically normal neonates; (3) to identify the source of NOS1 in 
umbilical cord blood; and (4) to simulate hypoxic events that may 
lead to NE and to evaluate production of NOS1 ex vivo.
MaTerials anD MeThODs
study Design
We undertook a nested case–control study within a prospective 
cohort of neonates, >35  weeks of gestation; cohort has been 
described previously (12). Cases were neonates with NE and con-
trols were age-matched newborns, admitted to the Johns Hopkins 
University Hospital (JHH) Neonatal Intensive Care Unit (NICU) 
between April 1, 2009 and May 30, 2014 (12). The Institutional 
Review Board at Johns Hopkins University School of Medicine 
approved this study, and all participants were anonymized.
Cases (Table  1) were neonates clinically diagnosed with 
moderate to severe NE, as defined by The American Academy 
of Pediatrics (5), who underwent whole-body cooling as per the 
JHH NICU institutional protocol which follows the recommen-
dations of Shankaran et al. (22). Controls (Table 1), matched with 
the cases by gestational age (within 1 week), were neurologically 
normal neonates.
For the secondary analysis, we created a subset that met strin-
gent criteria for NE cases and controls, based on clinical exam plus 
two additional criteria: umbilical cord arterial pH < 7.0 and base 
deficit >12 (Table 2) (23, 24). Neurologically normal neonates had 
a normal exam, umbilical artery pH > 7.2, and base deficit <8.
Maternal and neonatal characteristics
Maternal and neonatal records were reviewed, and pertinent 
clinical information was extracted. Data collected included infant 
sex, mode of delivery, gestational age, maternal age, parity, race, 
and three conditions suggested being risk factors for NE (25, 26): 
diagnosis of preeclampsia, clinical chorioamnionitis, and IUGR. 
Preeclampsia was defined as proteinuria and new onset hyperten-
sion. Clinical chorioamnionitis was defined as the presence of 
maternal fever with at least one other finding of fetal tachycardia, 
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uterine tenderness, or purulent vaginal discharge. IUGR was 
defined as an estimated fetal weight less than the 10th percentile 
for gestational age with ultrasound performed within 3  weeks 
after delivery date.
collection of Umbilical cord Blood  
for Determination of nOs1
Venous umbilical cord plasma was collected from routinely 
discarded collected blood. Samples were stored at −80°C until 
utilized.
Ex Vivo hypoxia of Umbilical cord
Umbilical cords were obtained from healthy full-term births 
within 4 h. Methods previously described by Thomas et al. (27); 
briefly, in a sterile cell culture hood, umbilical cord was cut 
into 1-mm length thick slices. For normoxia, specimens were 
cultured in a conventional incubator preset at 37°C in a humidi-
fied atmosphere, containing 5% CO2. Hypoxia was induced by a 
modular incubator chamber. To create gas hypoxia, specimens 
were first sealed in a humidified hypoxia incubator chamber 
system (Stemcell Technologies, Vancouver, BC, Canada) supplied 
with 1% O2 at 37°C according to the manufacturer’s instructions. 
After 3  h of incubation (simulating fetal hypoxic–ischemic 
event), umbilical cords were fixed with 4% paraformaldehyde 
(Affymetrix, Cleveland, OH, USA) overnight at 4°C for immuno-
histochemistry (IHC), or the tissue was trimmed close to the vein 
and artery followed by immediate storage at −80°C for western 
blot. Culture media was also collected and frozen at −80°C.
elisa for nOs1
ELISA of total NOS1 was performed according to the protocol 
established in our laboratory for indirect “sandwich” ELISA, 
optimized for highest sensitivity of human NOS1 in serum, 
amniotic fluid, or cell lysates. Briefly, an immobilized capture 
antibody for human NOS1 was coated overnight in 96-well 
microplate (R&D, Minneapolis, MN, USA). After blocking and 
sample incubation, the unbound material was washed away, 
and a biotinylated detection antibody specific for human NOS1 
(2 ng/ml, Cell Signaling Tech, Beverley, MA, USA) was used to 
detect the target protein utilizing a standard streptavidin-HRP 
format using 3,3′,5,5′-tetramethylbenzidine (TMB) as a substrate 
and subsequent reading at 450 nm. Biotinylation as well as prior 
purification of detection antibodies were done using biotinyla-
tion and protein A/G purification kits according to manufac-
turer’s recommendations (Pierce Biotechnology, Rockford, IL, 
USA). Recombinant purified NOS1 was purchased from Enzo 
Life Sciences, Inc. (Farmingdale, NY, USA) for standard curve. 
Average for blank readings was subtracted from the averages for 
the duplicate readings for each sample, and total NOS1 concentra-
tions of each sample were determined using log-linear regression. 
ELISA was further validated with JHH population with a separate 
group of samples.
immunohistochemistry
Using a cryostat (Leica, Buffalo Grove, IL, USA), umbilical cords 
were sectioned into 20-µm thick slices. Sections were incubated 
overnight at 4°C with primary antibodies in PBS containing 
0.5% Triton X-100 (Sigma, St. Louis, MO, USA) after block-
ing with 10% goat serum. The following primary antibodies 
were used: rabbit against NOS1 (1:1,000, Millipore, Billerica, 
MA, USA), NOS2 (1:20, Novus, Littleton, CO, USA), NOS3 
(1:100, Abcam, Cambridge, MA, USA), and mouse against CD34 
(1:500, Millipore, Billerica, MA, USA). CD34 was used to charac-
terize endothelial cells in human UC. The next day, sections were 
rinsed with PBS, and then incubated with fluorescent secondary 
antibodies diluted in 1:500 for 3 h at room temperature. The fol-
lowing antibodies were used for immunofluorescence: goat anti-
rabbit DyLight 488 (Abcam, Cambridge, MA, USA) and donkey 
anti-mouse Alexa Fluor 568 (Life Technologies, Grand Island, 
NY, USA). The sections were further stained with DAPI (Roche, 
Indianapolis, IN, USA) for 2 min at room temperature followed 
by mounting with Fluromount-G (eBioscience, San Diego, CA, 
USA). Images were attained using Axioplan 2 Imaging system 
(Carl Zeiss, Thornwood, NY, USA). To exclude a possibility that 
NOS1 positive cells were blood cells or of stem cell origin, double 
staining of NOS1/CD44 (Abcam, Cambridge, MA, USA) and 
NOS1/CD45 (Abcam, Cambridge, MA, USA) was also conducted.
To further confirm the distribution of NOS1 in human UC, 
another four NOS1 from hosts of rabbit or mouse (Cell Signaling, 
Beverly, MA, USA; Life Technologies, Frederick, MD, USA; 
Abcam, Cambridge, MA, USA; and BD Biosciences, Franklin 
Lakes, New Jersey, USA), one NOS2 (Abcam, Cambridge, MA, 
USA), and one NOS3 (Abcam, Cambridge, MA, USA) antibodies 
were utilized to exam the expression together with CD34 anti-
body. The secondary antibodies were used the same as described 
above.
sDs-Page and Western Blotting
The following were used as primary antibodies: rabbit against 
NOS1 (Millipore, Billerica, MA, USA), NOS2 (Novus, Littleton, 
CO, USA), NOS3 (Abcam, Cambridge, MA, USA) and rabbit 
anti β-actin (Abcam, Cambridge, MA, USA). Extracted protein 
(50 µg) was separated by SDS-PAGE using 4–15% gels (Bio-Rad 
Laboratories, Hercules, CA, USA) and then electro-transferred 
onto nitrocellulose membranes (Bio-Rad Laboratories, Hercules, 
CA, USA). Membranes were blocked with 10% BSA (Sigma-
Aldrich, St. Louis, MO, USA) in Tris-buffered saline  +  0.1% 
Tween-20 (TBS-T, pH7.5), incubated with primary antibodies 
in TBS-T containing 10% BSA for 1  h at room temperature, 
and washed in TBS-T. Goat anti-rabbit IR Dye-800CW (Li-Cor, 
Lincoln, NB, USA) was used as the secondary antibody. Imaging 
was performed using the Li-Cor Odyssey Near Infra Red System 
and analyzed using Image Studio Software (Li-Cor).
Quantitative Pcr (qPcr)
Vein and artery tissue were dissected from umbilical cords and 
frozen at −80°C until used. The tissue samples were homogenized 
in RLT buffer (Qiagen, Valencia, CA, USA) for 60  s using a 
BeadBug microtube homogenizer (Benchmark Scientific, Edison, 
NJ, USA) with 0.5-mm beads. Cord blood was collected into 
acid citrate dextrose tubes (BD Biosciences, Franklin Lakes, NJ, 
USA) and centrifuged at 400 × g for 10 min at room temperature. 
RNA was prepared from the umbilical cord homogenates and 
FigUre 1 | expression of nOs1 in umbilical cord blood. (a) Bar plot of relative absorbance in NOS1 level compared to controls based on exploratory 
NOS1-binding assay (n = 15 NE cases and 24 controls, Student’s t-test; *p < 0.05). (B) NOS1 concentrations were determined by ELISA using a separate  
set of patients (n = 12 NE cases and 13 controls; Student’s t-test; *p < 0.05). Data are reported as means ± SEM.
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cord blood leukocytes with RNEasy Mini Kit (Qiagen, Valencia, 
CA, USA), and cDNA was prepared using cDNA Synthesis Kit 
(Bio Rad, Hercules, CA, USA). qPCR was performed in triplicate 
in 20-µl reactions for 40 cycles, using the manufacturer’s suggested 
protocols for temperature cycling (Bio Rad, Hercules, CA, USA). 
The reactions were run on a CFX384 Touch Real-Time PCR 
Detection System (Bio Rad, Hercules, CA, USA), using SensiFAST 
Probe No-ROX (Bioline, Taunton, MA, USA). Primers used were 
obtained from Integrated DNA Technologies (Coralville, IA, 
USA) for NOS1 (Fwd: AGACGCACGAAGATAGTTGAC, Rev: 
CCGAAGCTCCAGAACTCAC, Probe:/56-AM/TCCTTAGCC/
ZEN/GTCAAAACCTCCAGAG/3IABkFQ), NOS2 (Fwd: 
ACTTCCACTTGCTGTACTCTG, Rev: CACCTACTTCCTG 
GACATCAC, Probe: CTGCTGCTCCAAAAGCTGGCC), and 
NOS3  (Fwd: ACGATGGTGACTTTGGCTA, Rev: TGGAGGATG 
TGGCTGTCT, Probe: CAGTGGAAATCAACGTGGCCGTG) 
or SsoAdvanced Universal SYBR Green Supermix (Bio-Rad) for 
Eukaryotic 18S Ribosomal RNA (Life Technologies, Grand Island, 
NY, USA). Data analysis was performed with CFX Manager 
Software (Bio Rad).
statistical analysis
Data were compared using Student’s t-test, Mann–Whitney U test, 
or Fisher exact test, when appropriate. Two-tailed Student’s t-test 
or Mann–Whitney U test was used subsequently to determine 
whether data were normally distributed. Fold change of NOS1 
level over mean control was calculated.
To determine the ability of NOS1 to predict NE, and the 
optimal cut points for NOS1, we created receiver operator charac-
teristic (ROC) curves. Sensitivity and specificity were determined 
for each of these points. Statistical analyses were performed using 
Stata10 (StataCorp LP, College Station, TX, USA).
resUlTs
study Population
Umbilical cord blood samples of 27 NE cases and 37 controls 
were used. There were no significant differences between cases 
and controls in: (i) maternal demographic parameters (gesta-
tional age at delivery, maternal age, nulliparous, and white race), 
(ii) incidence of adverse perinatal outcomes (preeclampsia, 
clinical chorioamnionitis, intrauterine growth restriction), or 
(iii) cesarean delivery or infant sex (Table 1). For an explora-
tory binding assay to detect NOS1 in umbilical cord blood of 
neonates, 15 NE and 24 control neonates were utilized. Eight 
neonates met stringent criteria for NE and were matched to 
ten control neonates (Table 2). Another 12 NE and 13 controls 
were utilized to validate the exploratory results by ELISA. We 
demonstrated the presence of NOS1 in the umbilical cord blood 
of all 64 neonates.
level of nOs1 in neonates with ne  
and in neurologically normal neonates
In our investigational study, as determined by relative absorbance 
values of ELISA (Figure 1A), the level of NOS1 in umbilical cord 
blood was significantly higher in NE cases (mean = 1.392 AU, 
95% CI 1.04–1.74) than in the controls (mean = 1.00 AU, 95% 
CI 0.77–1.23). Since these values were generated from a non-
commercial ELISA (prepared in our laboratory and originally 
without standards/standard curve), these findings were validated 
by a separate experiment to determine NOS1 concentration, 
involving separate set of samples and standards/standard curve 
(NE: mean = 1.32 ng/ml; Control: mean = 0.03 ng/ml; p < 0.05, 
Student’s t-test; Figure 1B).
stringent criteria subset
In umbilical cord blood, the mean relative absorbance of NOS1 
level was significantly higher (Figure  2A, p <  0.05, Student’s 
t-test) in the neurologically at-risk neonates meeting stringent 
criteria (mean =  2.006  AU, 95% CI 1.425–2.587) than in the 
neurologically normal control neonates (mean = 1.000 AU, 95% 
CI 0.493–1.507). Within the group of neonates meeting stringent 
criteria, NOS1 was predictive of NE. The ROC curve yielded an 
AUC of 0.84 for NOS1 prediction of NE (Figure 2B).
nOs1 expression in endothelial cells  
of human Umbilical Vein
To localize NOS1 in the human umbilical cord, IHC for NOS1 
and CD34 were performed. IHC for CD34 revealed a distribu-
tion of endothelial cells in the umbilical cord (28). NOS1 was 
FigUre 2 | nOs1 expression in ne patients classified by stringent criteria. (a) Relative absorbance of NOS1 expression compared to controls based on 
exploratory NOS1 binding assay (n = 8 NE cases and 10 controls, Student’s t-test; *p < 0.05). Bars represent mean ± SEM. (B) Receiver operator characteristic 
(ROC) curve for NOS1 expression. Area under the curve equals 0.84.
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expressed mainly in the form of fine granules in the cytoplasm 
and, occasionally, in cell membrane. There was a co-localization 
of NOS1 and CD34 in the umbilical vein, as demonstrated by 
double-positive staining (Figure 3A, top panel). Neither CD44 nor 
CD45 cells was co-localized with NOS1 (data not shown). There 
was no clear NOS1 expression in umbilical artery (Figure  3A, 
bottom panel). Western blot further confirmed IHC results with 
significant expression of NOS1 in umbilical vein (Figures 3B,C, 
Student’s t-test, p < 0.05).
Confirmatory analysis examining expression of NOS1, NOS2 
(inducible NOS), and NOS3 (endothelial NOS) at mRNA and pro-
tein level in umbilical cord and leukocytes were also performed. 
NOS1 was only detected in umbilical cord vein (Table 3), while 
NOS2 and NOS3 expression was detected by IHC and qPCR in 
both umbilical cord vein and artery. Transcripts for NOS1, NOS2, 
and NOS3 were not detected in cord blood leukocytes (Table 3) 
using qPCR.
To further ascertain a differential expression as well as to vali-
date the specificity of the antibodies used, another four NOS1, one 
NOS2, and one NOS3 antibodies were used in IHC. Similar to the 
above results, NOS1 expression was detected in umbilical cord 
vein but not in artery (Figure S1A in Supplementary Material). 
NOS2 (Figure S1B in Supplementary Material) and NOS3 (Figure 
S1C in Supplementary Material) were detected in both umbilical 
cord vein and artery.
Western Blot and elisa analyses of  
nOs1 expression in Ex Vivo Umbilical 
cord culture
To investigate whether hypoxia induces a NOS1 response in 
venous endothelial cells, umbilical cord slices were cultured in a 
hypoxia chamber under 1% O2. After 3 h of culture (simulating 
a clinical hypoxic event), the co-localization of CD34 and NOS1 
increased in the hypoxic group compared with normoxic control, 
by IHC (Figure 4A) and by western blot (Figures 4B,C, p < 0.05, 
Student’s t-test). We further measured NOS1 production in 
culture supernatant and, after 3  h of hypoxia, NOS1 increased 
significantly following hypoxic conditions (Figure 4D, Student’s 
t-test, p < 0.01).
DiscUssiOn
Our study is the first to demonstrate that NOS1, a marker of 
oxidative stress, is a potential early bedside clinical biomarker 
of NE in umbilical cord blood. In our study, the levels of 
NOS1 were significantly higher in the umbilical cord blood of 
neonates with clinical encephalopathy than in normal controls. 
Furthermore, our ex vivo experiments confirmed that NOS1 
was increased with hypoxia in venous endothelial cells of 
umbilical cord.
There are a few biomarkers relative to neonatal brain injury. 
NOS1 is currently the only early biomarker that is available to 
aid in diagnosis of NE at delivery based on umbilical cord blood. 
Massaro et al. evaluated the serum biomarkers S100B and NSE 
in neonates treated with hypothermia and found them to be 
associated with clinical encephalopathy and MRI change (3), 
consistent with prior studies (13–15, 29). None of the biomark-
ers were used for diagnosis or triage of neonates to therapy. In 
addition, the first time point evaluated was at initiation of cool-
ing; information was not available prior to initiation of cooling 
and could not assist with triage to therapy which represents a 
limitation of their study. Furthermore, others evaluated adre-
nomedullin and activin A have been evaluated as biomarkers 
of NE in neonatal serum but similarly have not been tested in 
umbilical cord blood (30). In Ennen’s studies (12), GFAP in 
serum at 24 and 48 h after birth was predictive of brain injury 
on MRI in encephalopathic neonates. Similarly to other markers 
discussed, at birth, umbilical cord blood GFAP levels were not 
predictive of brain injury.
We used ELISA for NOS1, which may present as a new, fast, 
and easy method to perform clinical test due to high levels (nano-
grams) of NOS1 presented in umbilical cord blood. As the AUC 
of NOS1 test is perhaps superior as compared to current clinical 
criteria for diagnosis of NE [AUC 0.81 (31)], we speculate that 
implementation of this test will improve sensitivity and specific-
ity of timely clinical diagnosis as it can be used concomitantly. 
Results of this test can be provided within the first several hours 
of life, allowing for early diagnosis and triage to therapy such as 
hypothermia and other novel therapeutics. One novel use for such 
clinical test would include early identification of which neonates 
TaBle 3 | Detection of nOs1, nOs2, and nOs3 in umbilical cord vein and 
artery.
immunohistochemistry 
(ihc)
Quantitative Pcr
nOs1 nOs2 nOs3 nOs1 nOs2 nOs3
Umbilical cord artery − (0/4) + (4/4) + (4/4) − (0/4) + (4/4) + (3/4)
Umbilical cord vein + (4/4) + (4/4) + (4/4) + (3/4) + (4/4) + (3/4)
Cord blood 
leukocytes
− (0/4) − (0/4) − (0/4)
−, negative expression; +, positive expression. There were four samples for each 
group. In brackets, numerators are the numbers tested negative or positive expression 
by IHC or quantitative PCR.
FigUre 3 | nOs1 expression in vessels of human umbilical cord. (a) Immunostaining of CD34 and NOS1 in endothelial cells of vein and artery of umbilical 
cord (n = 4 per group). (B) Protein expression of NOS1 in vein and artery of umbilical cord by western blot. (c) Densitometry analysis of western blot imaging  
(n = 5 per group; Student’s t-test; *p < 0.05). Scale bars = 100 µm.
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that might benefit from storage of umbilical cord blood for later 
stem cell transplantation and would result in timely collection of 
umbilical cord blood.
Neonatal encephalopathy is a rare diagnosis and MRI 
diagnosis of actual brain injury in this group is an infrequent 
finding. The consequences of NE including death and neu-
rodevelopmental disability can be devastating for the child and 
family. While one critique of our study could be a small sample 
size, the nested case–control study represents a valuable sample, 
given that NE is rare, even in our referral university center. 
However, our data are confirmed with simulation of hypoxia 
ex vivo, and this is an advantage of our study. Further research 
will concentrate on collecting information about childhood 
outcomes of these at-risk neonates with neurodevelopmental 
testing at 1–3 years of age.
Our study has several strengths. An ELISA assay quantified 
the level of NOS1, and this test can be used in a clinical setting 
to inform clinical decisions early in neonatal life. The results are 
reproducible, and more stringent criteria for encephalopathy 
yields improved prediction of NOS1 for NE. In addition to 
identifying neonates at risk of brain injury, a biomarker would 
timely predict which infants are at risk for brain injury and which 
are most likely to have long-term neurologic sequelae. Moreover, 
our study identifies a source of NOS1, and, using experimental 
conditions that mimic short-term hypoxic environments, we are 
able to observe similar findings ex vivo.
Perinatal hypoxia–ischemia is an important cause of NE (50–
80%) (32). Nitric oxide signaling has been demonstrated to have 
an important role in hypoxia-induced pathological responses 
as all NOS isoforms critically require oxygen for activity (33). 
Physiologically, NOS1 depends more on oxygen and has higher 
rates of nitric oxide biosynthesis (34) than NOS2 and NOS3. 
Both NOS1 mRNA and protein expression are regulated by O2 at 
transcriptional and translational level (35, 36), and therefore, it 
may be more sensitive to hypoxia. Corollary to that, in our study, 
NOS1 significantly increased in umbilical cord blood of moderate 
and severe NE neonates compared to control.
To investigate a plausible origin of NOS1 in umbilical cord 
blood, we performed a survey of all possible sources of NOS1 
in umbilical cord blood and umbilical cord. We found that 
NOS1 was present in endothelial cells of human umbilical cord 
FigUre 4 | nOs1 expression in endothelial cells of human umbilical vein in 1% hypoxic chamber. (a) Immunostaining of CD34 and NOS1 in vein  
(n = 5 per group). (B,c) Protein levels of NOS1 in umbilical cord by western blot (n = 5 per group; Student’s t-test; *p < 0.05). (D) NOS1 production in ex vivo 
culture supernatant by ELISA (n = 5 per group; Student’s t-test; **p < 0.01). Scale bars = 10 µm.
7
Lei et al. NOS1 in Umbilical Blood of NE
Frontiers in Pediatrics | www.frontiersin.org May 2017 | Volume 5 | Article 112
vein but not in umbilical cord artery. While our results are in 
keeping with a previous study (20) that showed NOS1 expres-
sion in vein of human umbilical cord by IHC, our study is the 
first to demonstrate a differential expression of this enzyme in 
umbilical vein and artery. In the adult vascular system, NOS1- 
and NOS3-derived nitric oxide is thought to play a major role 
in changes of vascular arterial tone (37, 38). In addition to 
regulating vascular tone, nitric oxide is an important signal-
ing molecule in the nervous system and the immune system 
(39, 40). We speculate that endothelial NOS1 expression in 
umbilical vein may be a conserved mechanism that contributes to 
the fetal response to hypoxia and inflammation. Further studies 
to clarify the role of umbilical cord NOS1 during hypoxic and 
inflammatory conditions are needed.
In conclusion, we speculate that NOS1 is a novel, early 
biomarker for early identification of NE that can be used in 
determining NE together with clinical manifestations to improve 
diagnosis, allowing for better prognostic information and earlier 
interventions.
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